PDL anti-CMV monoclonal antibody trials

6 August 1995

- PDL has started a Phase II trial of its human monoclonal anti-CMV antibody MSL-109 in AIDS patients suffering from cytomegalovirus retinitis. The trial has been sponsored by the US National Institute of Allergy and Infectious Diseases' AIDS Clinical Trials Group. Further to this, the company has also contracted a separate Phase II/III study of the drug to the Studies of the Ocular Complications of AIDS group at Johns Hopkins University. A date for this trial has not yet been set.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight